Monoclonal Antibodies Market in Colorectal Cancer @

1. Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising
Prevalence in Europe and Japan Ensures Market Growth
GBI Research, has released the pharma report - “Monoclonal Antibodies Market in Colorectal Cancer
to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market
Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic
colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix.
The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of
oncology indications. While compelling late-stage candidates are absent from the current pipeline, the
anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment.
Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent
expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI
Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.
Scope
A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis
and treatment algorithms. In-depth analysis of the three mAbs marketed for colorectal cancer, including
analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing
the drugs in terms of safety and efficacy. A comprehensive review of the pipeline for colorectal cancer
therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the
market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types,
program types, mechanisms of action and molecular targets. Additional in-depth analysis of pipeline drug
clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to
an in-depth analysis of clinical trial primary endpoints. Multi-scenario forecast data of the market to 2019,
taking into account how the market may be affected by the introduction of new drugs, the expiry of key
patents on current drugs and the changes in disease epidemiology across the key developed markets.
Discussion of the drivers and barriers for market growth. In-depth analysis of all licensing and
co-development deals that have occurred in the colorectal cancer market since 2006.
Reasons to Buy
Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and
targeted small molecule therapies. Understand the vast scope of the pipeline, including which molecule types
and mechanisms of action are prominent. Observe the trends in clinical trial duration and size amongst clinical
phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current
and/or future developmental programs for colorectal cancer therapeutics. Observe the shift in clinical trial
endpoints throughout clinical phases of development, and use this data to potentially influence any future
developmental programs. Assess the potential clinical and commercial impact of current late-stage pipeline
molecules in the colorectal cancer mAbs market.
table Of Contents
1 Table Of Contents 1
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan

2. 1.1 List Of Tables 3
1.2 List Of Figures 4
2 Executive Summary 5
2.1 Monoclonal Antibodies Favored In The Market For Metastatic Colorectal Cancer 5
2.2 Strong Pipeline To Drive Growth To 2019 5
3 Monoclonal Antibodies In Colorectal Cancer Market To 2019 – Introduction 7
3.1 Symptoms 7
3.2 Etiology 7
3.3 Epidemiology 8
3.4 Pathophysiology 9
3.5 Diagnosis 9
3.6 Prognosis And Disease Staging 10
3.7 Treatment Options 11
3.7.1 Chemotherapy 11
3.7.2 Targeted Therapies 12
3.7.3 Resistance To Pharmacological Therapies 13
3.7.4 Treatment Guidelines 13
3.8 Gbi Research Report Guidance 15
4 Monoclonal Antibodies In Colorectal Cancer Market To 2019 – Marketed Products 16
4.1 Avastin (bevacizumab) – Hoffman La Roche 16
4.2 Erbitux (cetuximab) – Bristol-myers Squibb, Eli Lilly, And Merck Kgaa 18
4.3 Vectibix (panitumumab) – Amgen And Takeda 19
4.4 Heat Map For Marketed Products 20
4.5 Conclusion 22
5 Monoclonal Antibodies In Colorectal Cancer Market To 2019 – Developmental Pipeline 23
5.1 Overall Pipeline 23
5.2 Molecular Targets And Mechanisms Of Action 25
5.3 Clinical Trials 26
5.3.1 Failure Rate 26
5.3.2 Clinical Trial Size 27
5.3.3 Duration 30
5.3.4 Primary Endpoints 31
5.4 Conclusion 33
5.5 Key Late-stage Pipeline Products 33
5.5.1 Imc-1121b (ramucirumab) – Eli Lilly And Company 33
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan

3. 5.5.2 Xilonix – Xbiotech 34
5.5.3 Metmab (onartuzumab) – Hoffmann-la Roche 34
5.5.4 Anti-dr5 Moab (tigatuzumab) – Daiichi Sankyo 34
5.5.5 Mk0646 (dalotuzumab) – Merck 35
5.5.6 Amg-655 (conatumumab) – Amgen 36
5.6 Conclusion 36
6 Monoclonal Antibodies In Colorectal Cancer Market To 2019- Market Forecast To 2019 36
6.1 Global 38
6.1.1 Treatment Usage Patterns 38
6.1.2 Market Size 39
6.2 North America 40
6.2.1 Us 40
6.2.2 Canada 42
6.3 Europe 43
6.3.1 Treatment Usage Patterns 43
6.3.2 Annual Cost Of Therapy 44
6.3.3 Market Size 46
6.4 Japan 47
6.4.1 Treatment Usage Patterns 47
6.4.2 Market Size 48
6.5 Drivers And Barriers 48
6.5.1 Drivers 48
6.5.2 Barriers 49
7 Monoclonal Antibodies In Colorectal Cancer Market To 2019- Deals And Strategic Consolidations 51
7.1 R&d Licensing Agreements 51
7.1.1 Key Licensing Deals 54
7.2 Co-development Agreements 56
7.2.1 Key Co-development Agreements 57
8 Monoclonal Antibodies In Colorectal Cancer Market To 2019- Appendix 58
8.1 Market Definitions 58
8.2 Abbreviations 58
8.3 References 60
8.4 Sources For Heat Map 65
8.5 All Pipeline Products, By Stage Of Development 66
8.5.1 Discovery 66
8.5.2 Preclinical And Ind/cta-filed 67
8.5.3 Phase I 72
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan

4. 8.5.4 Phase Ii 75
8.5.5 Phase Iii And Pre-registration 80
8.5.6 Undisclosed 80
8.6 Tabular Forecast Data 82
8.6.1 Global 82
8.6.2 Us 82
8.6.3 Canada 82
8.6.4 Uk 82
8.6.5 France 83
8.6.6 Germany 83
8.6.7 Italy 83
8.6.8 Spain 83
8.6.9 Japan 84
8.7 Research Methodology 84
8.7.1 Coverage 84
8.7.2 Secondary Research 84
8.7.3 Primary Research 85
8.7.4 Therapeutic Landscape 85
8.7.5 Epidemiology-based Forecasting 85
8.7.6 Market Size By Geography 87
8.7.7 Geographical Landscape 88
8.7.8 Pipeline Analysis 88
8.8 Contact Us 88
8.9 Disclaimer 88
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan

5. Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan